Links to prescribing information and adverse event reporting information can be found at the bottom of the page. For UK Healthcare professionals only.
ABOUT Vectibix®
Treating with
Vectibix®
ABOUT Vectibix®
Vectibix® is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC)1:
- In first-line in combination with FOLFOX or FOLFIRI
- In second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)
- As monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens
What is Vectibix® (panitumumab)?
Vectibix® is a recombinant, fully human anti-epidermal growth factor receptor inhibitor (EGFRI) monoclonal antibody.1
Mechanism of action:
Vectibix® is an antibody that binds with high affinity and specificity to the human epidermal growth factor receptor (EGFR) and inhibits receptor autophosphorylation induced by all known EGFR ligands.1
Binding of Vectibix® to EGFR results in1:
- Internalisation of the receptor
- Inhibition of cell growth
- Induction of apoptosis
- Decreased interleukin-8 and VEGF production
Panitumumab – a fully human monoclonal antibody (mAB) – inhibits epidermal growth factor receptor (EGFR) ligand binding and receptor dimerisation
- Fully human, IgG2 mAb2
- Binds with high affinity and specificity to the extracellular domain of the human epidermal growth factor receptor (EGFR)1
- Dissociation constant: KD = 0.05 nM2,3
- Inhibits receptor activation of all known EGFR ligands4
- Inhibits EGFR-dependent activity including cell activation and cell proliferation in various preclinical models2,3
IgG2, immunoglobulin G2; mAb, monoclonal antibody.
References
- Vectibix® Summary of Product Characteristics.
- Foon KA, et al. Int J Radiat Oncol Biol Phys 2004;58:984−90.
- Yang XD, et al. Cancer Res 1999;59:1236−43.
- Freeman D, et al. J Clin Oncol 2008;26(Suppl 15):abstract 14536.